What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “dose-escalation and dose-expansion of GM103 in combination with pembrolizumab, conducted in approximately 61 patients. Part C of the study will include a screening period of up to 28 days, a safety run-in period of 2 cycles (it consists of 2 cohorts and the first 1 cycle for the DLT assessment period of each cohort is included, each cycle will consist of 21 days \[3 weeks\]), and a dose expansion…”In the company’s words, NCT06265025 on ClinicalTrials.gov
- Tested for
- Head and Neck Cancer, Malignant Melanoma, Colorectal Cancer, Renal Cell Carcinoma, Cervical Cancer, Breast Cancer
- Main trialPhase 1/2
- “The purpose of this study is to measure safety, tolerability, and preliminary antitumor efficacy of GM103 administered alone and in combination with pembrolizumab in patients with locally advanced, unresectable, refractory and/or metastatic solid tumors (including but not limited to head and neck cancer, malignant melanoma, CRC, renal cell carcinoma, cervical cancer, and breast cancer). Study details include:”In the company’s words, NCT06265025 on ClinicalTrials.gov
Other drugs for Head and Neck Cancer
- Izalontamab brengitecanSichuan Baili (Biokin, SystImmune) · Bristol Myers Squibb · Phase 3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- BupiZengeOncoZenge AB · Phase 3
- KC1036Beijing Konruns Pharmaceutical Co., Ltd. · Phase 3
- APG-157Aveta Biomics, Inc. · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 30 May 2025 | GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026